SGLT-2 inhibitorsCardiovascular diseaseType 2 diabetes mellitusDiabetic nephropathyChronic kidney diseaseRisk reductionIn addition to being a leading cause of end-stage renal disease, diabetes mellitus is also associated with an elevated risk of heart failure. A new class of anti-hyperglycaemic drugs...
ChemicalBook provide Chemical industry users with IPRAGLIFLOZIN (SGLT2 Inhibitor)() Boiling point Melting point,IPRAGLIFLOZIN (SGLT2 Inhibitor)() Density MSDS Formula Use,If You also need to IPRAGLIFLOZIN (SGLT2 Inhibitor)() Other information,welcome to
此外,在本发明中提供了药物组合物,其包含SGLT2抑制剂以及碳水化合物补剂或尿酸合成抑制剂或碳水化合物补剂和尿酸合成抑制剂,还提供了在本发明方法中的应用. In the present invention provides a pharmaceutical composition comprising a SGLT2 inhibitor and an inhibitor of uric acid synthesis or a supply of ...
SGLT2-InhibitorHerzinsuffizienzDiabetesSodium-glucose co-transporter 2 (SGLT2) inhibitors can block glucose reabsorption in the proximal tubule and thus play an important role in glycemic control in diabetes mellitus. In addition to glucosuric effects, surprisingly very extensive other positive effects ...
C-ARYL-GLUCOSID-SGLT2-INHIBITORENELLSWORTH BRUCEWASHBURN NSHER MWU GANGMENG WEI
Ketoacidosis induced by sodium-glucose cotransporter2 inhibitors (SGLT-2i) is rare. If it occurs, it is aserious clinical condition which requires immediate and correct treatment. At the moment, the occurrence of aketoacidotic crisis necessitates permanent removal of the SGLT-2i from the patient...
C-Arylglucosid SGLT2-Inhibitoren und Verfahren C-aryl glucosides SGLT2 inhibitors and methodsBruce Princeton ELLSWORTHWei Pennington MENGM. Philip Plainsboro SHERN. William Titusville WASHBURNGang Princeton WU
We recently showed a direct cardiac class effect of SGLT2i; SGLT2i inhibit sodium hydrogen exchanger 1 (NHE-1), reduce [Na + ] c and induce vasodilation in the healthy heart. Here, we studied if the SGLT2i empagliflozin (EMPA) improves endothelial function during TNF-α induced ...
Wei MengPhilip M. SherWilliam N. WashburnGang WuEPEP1224195B1 Oct 2, 2000 May 18, 2005 Bristol-Myers Squibb Company C-aryl glucoside sglt2 inhibitorsEP1224195B1 2000年10月2日 2005年5月18日 Bristol-Myers Squibb Company C-aryl glucoside sglt2 inhibitors...
Effect of SGLT-2 inhibitors on impaired ventricular repolarizationAmid the excitement over the results of the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial (1), the potential mechanisms through which empagliflozin produced a ...